HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

By sjmartinez • May 24, 2024

Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA; HPTN 083‐02 Study Team. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252. PMID: 38783534.

Tags: HIV prevention, Infectious Diseases, Injectable PrEP, Men who have sex with men, pre‐exposure prophylaxis, Publications, qualitative, Transgender women

Related Posts

Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson[...]

Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US

Pei PP, Jones M, Hu R, Chen W, Sax PE, Pandya A, Gandhi M, Eron JJ, Currier JS, Wilkin TJ, Reddy KP, Qoshe L, Hyle[...]